Rocket Pharmaceuticals (RCKT) Current Leases (2019 - 2025)
Historic Current Leases for Rocket Pharmaceuticals (RCKT) over the last 7 years, with Q3 2025 value amounting to $1.9 million.
- Rocket Pharmaceuticals' Current Leases rose 298.59% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 298.59%. This contributed to the annual value of $1.9 million for FY2024, which is 362.93% up from last year.
- As of Q3 2025, Rocket Pharmaceuticals' Current Leases stood at $1.9 million, which was up 298.59% from $1.9 million recorded in Q2 2025.
- Rocket Pharmaceuticals' 5-year Current Leases high stood at $1.9 million for Q3 2025, and its period low was $1.7 million during Q1 2021.
- Moreover, its 5-year median value for Current Leases was $1.8 million (2023), whereas its average is $1.8 million.
- The largest annual percentage gain for Rocket Pharmaceuticals' Current Leases in the last 5 years was 1197.56% (2021), contrasted with its biggest fall of 273.72% (2021).
- Rocket Pharmaceuticals' Current Leases (Quarter) stood at $1.7 million in 2021, then increased by 2.78% to $1.7 million in 2022, then increased by 3.17% to $1.8 million in 2023, then increased by 3.63% to $1.9 million in 2024, then increased by 2.21% to $1.9 million in 2025.
- Its Current Leases was $1.9 million in Q3 2025, compared to $1.9 million in Q2 2025 and $1.9 million in Q1 2025.